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Abstract
One strategy adopted by vaccinia virus (VV) to evade the host immune system is to encode
homologs of TNF receptors (TNFR) that block TNFα function. The response to VV skin infection
under conditions of TNFα deficiency, however, has not been reported. We found that TNFR1−/−
mice developed larger primary lesions, numerous satellite lesions and higher skin virus levels after
VV scarification. Following their recovery, these TNFR1−/− mice were fully protected against
challenge with a lethal intranasal dose of VV, suggesting these mice developed an effective
memory immune response. A functional systemic immune response of TNFR1−/− mice was
further demonstrated by enhanced production of VV-specific IFNγ and VV-specific CD8+ T cells
in spleens and draining lymph nodes. Interestingly, bone marrow (BM) reconstitution studies
using WT BM in TNFR1−/− host mice, but not TNFR1−/− BM in WT host mice, reproduced the
original results seen in TNFR1−/− mice, indicating that TNFR1 deficiency in resident skin cells,
rather than hematopoietic cells, accounts for the impaired cutaneous immune response. Our data
suggest that lack of TNFR1 leads to a skin-specific immune deficiency and that resident skin cells
play a crucial role in mediating an optimal immune defense to VV cutaneous infection via TNFα/
TNFR1 signaling.
Introduction
Vaccinia virus (VV) is a large double stranded DNA virus belonging to the poxvirus family.
Like other poxviruses, VV has evolved elegant and sophisticated mechanisms to evade
detection and destruction by the host immune system. Among the evasion strategies adopted
by VV is to encode homologs of cytokines, chemokines and their receptors that play crucial
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troles in control of the immune response (Seet et al., 2003). Since TNFα is a potent
inflammatory cytokine that can orchestrate communication between innate and adaptive
immune responses, it is not surprising that VV has developed mechanisms to interfere with
the TNFα/TNFR pathway. The best characterized anti-TNFα strategy employed by VV is to
encode homologs of TNFR, termed vTNFR, that can bind and sequester TNFα (Reading et
al., 2002). In contrast, recombinant VV expressing the gene for murine TNFα demonstrated
attenuated virulence in vivo (Sambhi et al., 1991).
Within the normal host, TNFα is produced principally by macrophages and activated T cells.
TNFα-mediated effects are critically important in the response to a variety of infections
caused by bacteria, protozoa, fungi and viruses (Schluter and Deckert, 2000). For VV in
particular, it has been reported that mice deficient in TNFα or TNF receptors are more
susceptible to intraperitoneal (i.p.) and intravascular (i.v.) infections. (Nie et al., 2009; Ruby
et al., 1997). The mechanism and outcome of cutaneous VV infection is not necessarily
expected to be the same as these systemic infections and the role of TNFα following
cutaneous infection is less well defined. Although routine vaccination against smallpox was
discontinued in the United States in 1972, the potential for use of the smallpox virus as a
bioterror agent and the endemic presence of monkeypox virus in Africa has resulted in
continued use of smallpox vaccines in medical, military and at-risk populations (Rimoin et
al., 2010). Effective smallpox vaccination in humans is commonly achieved by inoculating
skin with live VV via scarification. Inoculation via other routes, or use of killed virus
vaccines, is known to result in inferior protective responses in humans (McClain et al.,
1997). We have also demonstrated that VV scarification elicits stronger T cell and humoral
responses, compared to other routes of immunization in mice (Liu et al., 2010). However,
smallpox vaccination by scarification can lead to uncontrolled virus replication, known as
eczema vaccinatum (EV), in patients with atopic dermatitis (AD) and immune deficiency
disorders, resulting in devastating morbidity and mortality (Engler et al., 2002).
This study explores the impact of TNFα/TNFR1 deficiency on the outcome of cutaneous
VV infection. After VV scarification, TNFR1−/− mice demonstrated an impaired cutaneous
immune response with a phenotype that resembled EV. Investigation of innate and adaptive
immune responses in TNFR1−/− mice showed no difference in effector or memory immune
responses. The results of bone marrow reconstitution studies suggest that the impaired
cutaneous response was caused by TNFR1 deficiency of resident skin cells.
Results
1. TNFR1 deficient mice developed markedly larger skin lesions with higher virus counts
compared to WT mice following VV scarification
Mice were scarified with WR-VV at the base of the tail and observed for the development of
pox lesions. Seven days after VV scarification, TNFR1−/− mice exhibited lesions that were
at least 2-fold larger than lesions on WT control mice. At day 14, the differences in skin
lesions were more dramatic, as multiple satellite lesions appeared on the TNFR1−/− mice
and the lesions on WT mice started to heal. By day 21, TNFR1−/− mice showed signs of
skin healing, but their lesions were still markedly larger than WT controls (Figures 1a, 1b
and 1c). To confirm the effect of TNFα on skin lesions, WT mice were treated with
function-blocking anti-TNFα mAb or control Ab. Anti-TNFα mAb treatment led to
significantly larger lesions in WT mice following VV scarification, consistent with the
results seen in TNFR1−/− mice (Figure 1d). In both studies, all mice ultimately survived
and skin lesions resolved by day 28 – 35. These data indicate that disruption of the TNFα/
TNFR1 pathway leads to exacerbation of skin lesions following VV scarification.
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tTo investigate whether the enhanced skin lesions were associated with virus replication and
dissemination, we measured the virus load of inoculated tail skin and skin adjacent to the
pox lesion. We found that TNFR1−/− and WT mice possessed comparable levels of virus in
inoculated skin one week after VV scarification. Two weeks after scarification, TNFR1−/−
mice had slightly higher virus loads in the inoculated skin than WT controls. (Figure 1e). In
contrast, analysis of skin samples adjacent to scarification sites revealed that the skin of
TNFR1−/− mice contained at least 100 fold more virus than that of WT mice one week after
VV scarification and 10 times more virus two weeks after scarification (Figure 1f). Thus,
TNFR1−/− mice have a defect in controlling local VV replication and dissemination, which
might contribute to the formation of larger skin lesions. To investigate whether the impaired
cutaneous response of TNFR1−/− mice to VV scarification reflected a global impairment or
a skin-specific immune dysfunction, we measured viral load in peripheral organs and found
that TNFR1−/− mice and WT mice had comparable viral burdens in ILN, spleen, lung and
liver for up to two weeks post scarification and both cleared VV from peripheral organs by
three weeks (Figure S1). The impaired host response of TNFR1−/− mice to VV
scarification, therefore, appears to be restricted to skin.
2. Humoral immune response was reduced in TNFR1−/− mice following VV scarification,
although survival from intranasal challenge was not affected
To investigate the mechanisms underlying the impaired cutaneous response of TNFR1−/−
mice after VV scarification, we compared the production of VV-specific Ab between
TNFR1−/− and WT mice following VV scarification. Total VV-specific IgG levels in
TNFR1−/− mice were similar to those in WT mice up to three weeks after VV scarification
but significantly less than those in WT mice at four weeks and later. Interestingly, TNFR1−/
− mice did not generate significant VV-specific IgG1 at any time point, yet their production
of IgG2a was comparable to WT controls (Figure 2a). These results indicate that the
humoral immune response in TNFR1−/− mice was impaired following VV scarification.
However, the observation that TNFR1−/− and WT mice produced comparable levels of VV-
specific Ab during two weeks following scarification indicates that the difference in lesion
size and character seen in TNFR1−/− mice was not caused by inferior VV-specific Ab
production. To confirm generation of systemic immunity, we challenged TNFR1−/− and
WT mice six weeks after VV scarification with a lethal intranasal dose of WR-VV. All of
the immunized mice survived the challenge while unimmunized mice lost body weight at the
same rate and died within one week (Figure 2b). Thus, the reduced humoral response did not
impair systemic immune protection to subsequent lethal challenge in TNFR1−/− mice.
3. Type 1 T cell immune response was enhanced in TNFR1−/− mice following VV
scarification
To determine whether the altered cutaneous response of TNFR1−/− mice was due to a
defect in T cell immune responses, we used in vitro restimulation assays to detect VV-
specific cytokine production and VV B8R20–27 peptide (TSYFESV)/MHC pentamer
staining to enumerate VV-specific CD8+ T cells in spleens and ILNs. Similar levels of VV-
induced IFNγ were produced by spleen cells from TNFR1−/− and WT mice 7 days
following WR-VV scarification. Surprisingly, by days 14 and 30, the level of IFNγ secreted
by spleen cells from TNFR1−/− mice was significantly higher than that for WT mice. ILN
cells from VV scarified TNFR1−/− mice produced significantly more IFNγ than WT ILN
cells at all observed time points (Figure 3a). No significant production of IL-4 or IL-10 was
detected from the spleen or ILN cells of VV inoculated mice of either strain (data not
shown).
Consistent with the results of in vitro restimulation assays, spleens of TNFR1−/− mice
contained similar numbers of VV-specific CD8+ T cells as compared to WT mice at day 7
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tpost scarification. At day 14 and 30, TNFR1−/− mice had significantly more VV-specific
CD8+ T cells evident in the spleen. TNFR1−/− mice displayed a greater number of VV-
specific CD8+ T cells in the ILN at all observed time points (Figure 3b, 3c). These data
suggest TNFR −/− mice are not deficient in production of CD8+ effector cells.
To address the possibility that the increased Th1 response in TNFR1−/− mice could be due
to greater antigen levels, resulting from the higher virus counts in the skin, we scarified mice
with MVA, a strain of VV that does not replicate in mammalian cells. As seen with VV,
spleen cells of MVA-scarified TNFR1−/− mice produced similar levels of IFNγ at day 7
and higher levels at days 14 and 30 when compared to WT mice. ILN cells of TNFR1−/−
mice also produced more IFNγ than WT mice at day 7 (Figure 3d). These results indicate
that the enhanced Th1 cytokine production observed in TNFR1−/− mice is independent of
antigen load. Furthermore, lesion size was similar between TNFR1−/− and WT mice
following MVA scarification (data not shown), suggesting that the larger lesions and
satellite lesions observed in TNFR1−/− mice after VV scarification reflect the cytopathic
effect of replicating vaccinia virus. Collectively, these data indicate that the altered
cutaneous response of TNFR1−/− mice following VV scarification was not caused by a
defect of T cell activation, production of VV-specific CD8+ effector cells or Th1 helper
response. In fact, TNFR1−/− mice had an enhanced type 1 T cell response as compared to
WT mice.
4. T cell homing to the inoculation site was not altered by TNFR1 deficiency
The impaired cutaneous response of TNFR1−/− mice might indicate a defect in T cell
homing to skin following VV scarification. However, comparable CD3+ T cell infiltration
was found in the lesions of TNFR1−/− mice and WT mice six days post VV scarification
(Figure 4a). To assess the kinetics of T cell skin homing, we performed FACS analysis on
cells recovered from tail skin at different time points following VV scarification and found
similar ratios of CD4+ and CD8+ T cells recruited to the inoculated skin of TNFR1−/− and
WT mice (Figure 4b). Given that the total number of skin cells recovered was slightly higher
in TNFR1−/− mice than WT mice (data not shown), these results suggest that TNFR1−/−
mice could recruit CD4+ and CD8+ T cells to skin at least as efficiently as WT mice.
To further explore the influence of TNFR1 deficiency on VV-specific CD8+ T cell skin
homing, we also performed B8R-pentamer staining. At day 3 post VV scarification, very
few CD8+ T cells were present in the inoculated skin of either TNFR1−/− or WT mice
(Figure 4c). At day 7, both TNFR1−/− and WT had substantial numbers of CD8+ T cells
present in the inoculation site, with a similar fraction of CD8+ T cells staining with B8R
pentamer (TNFR1−/−: 18.7%; WT: 19.5%) (%B8R within CD8+ = %B8R+CD8+/ (%B8R+
CD8+ + %B8R− CD8+) * 100). On days 14 and 30, TNFR1−/− mice continued to show
slightly higher %B8R-pentamer positive CD8+ T cells than WT controls.
Alternative explanations for the impaired cutaneous immune response in TNFR1 −/− mice
could reflect enhanced recruitment of regulatory T cells (Tregs) to the site of inoculation
(Rouse et al., 2006) or altered functions of the VV-specific CD8 effector cells present in the
site. We found the fraction of CD4+CD25+FoxP3+ Tregs in inoculated skin were
comparable in WT and TNFR1−/− mice (23.4% and 22.6%, respectively) (Figure S2a).
Furthermore, CD8+B8R+ T cells from TNFR1−/− mice produced similar levels of IFNγ and
granzyme B in response to in vitro stimulation as compared to WT mice. (Figure S2a and
S2b). These results suggest that VV-specific CD8+ T cells recruited to the inoculated skin
are not defective or suppressed and general T cell homing to the skin is operational in
TNFR1−/− mice following VV scarification.
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t5. Impaired cutaneous response to VV scarification is associated with TNFR1 deficiency of
resident skin cells and not of BM-derived hematopoietic cells
The development of pox lesions in VV scarified mice involves both BM derived cells that
are recruited to the skin as well as skin stromal cells, including keratinocytes and fibroblasts.
To distinguish which of these two cell populations utilized TNFα/TNFR1 signaling to
control virus dissemination and skin lesion formation, we generated three groups of chimeric
mice: (1) TNFR1−/− BM →WT host, (2) WT BM→ TNFR1−/− host and (3) WT BM→
WT host. Chimeric mice were inoculated with VV approximately 8 weeks after irradiation
and bone marrow reconstitution. By day 12 after VV scarification, WT BM→TNFR1−/−
mice developed multiple satellite lesions and had significantly larger lesions than both WT
BM → WT and TNFR1−/− BM →WT mice (Figure 5a), a phenotype that is strikingly
similar to that of non-irradiated/ non-reconstituted TNFR1−/− mice.
Assessment of viral load in lesional and adjacent skin confirms the gross impression. VV
DNA copy number was similar within lesional skin of all three chimeric mouse populations.
Assessment of adjacent skin, however, shows high viral load in WT BM→TNFR1−/− mice
while TNFR1−/− BM →WT and WT BM → WT chimeric mice contained only trace
amounts of virus (Figure 5b). From this data, we conclude that the lack of TNFR1 in
radioresistant skin cells, as opposed to circulating BM-derived cells, is the key factor
associated with more vigorous local virus replication and dissemination and leads to the
development of larger skin lesions and satellite lesions in VV scarified TNFR1−/− mice.
Since the impaired cutaneous response to VV scarification of TNFR1 deficient mice
appeared to reflect a malfunction of skin stromal cells, we explored potential mechanisms
that might lead to this susceptibility. Toward this end, we performed immunohistochemical
staining of mouse skin inoculated with VV-GFP. Interestingly, the degree of keratinocyte
staining was similar in WT and TNFR1−/− mice. In contrast, VV-GFP was detected in
numerous dermal mesenchymal cells in the superficial and deep layers of skin in TNFR1−/−
mice while these areas were devoid of staining in WT mice (Figure 5c).
Given the evidence that the critical cells responding to TNF in this model are radioresistant,
we entertained the possibility that the increase in VV replication and dissemination observed
in TNFR1−/− mice could be due to an inability to upregulate innate antiviral mechanisms in
response to VV scarification. The antimicrobial protein cathelicidin (or CRAMP in mice)
has been shown to posess critical antiviral activity against VV in both human and mouse
skin. Murine CRAMP knockout mice exhibited reduced ability to control VV replication
and dissemination in skin (Howell et al., 2006; Howell et al., 2004). We compared CRAMP
gene expression in skin from WT and TNFR1−/− mice and found that 12 hours following
VV scarification, CRAMP gene expression was approximately 4-fold higher in the
inoculated skin of WT mice than TNFR1−/− mice (Figure 5d). CRAMP gene expression
was low in distant skin of both groups at all observed time points. These results suggest that
the inability of skin stromal cells to upregulate CRAMP in response to TNF stimulation may
be the fundamental defect in TNFR1 deficient mice.
Discussion
In this study, we have shown that WT mice were able to control VV replication in epidermis
after scarification and that VV-specific T cells were generated and able to eliminate VV by
week 3. In the absence of TNFR1, VV was able to infect a broader area of skin including
epidermal, dermal and subcutaneous layers. T cells still developed and were able to
eliminate virus, but larger lesions and tissue damage were observed. We went on to show
that this outcome in TNFR1−/− mice is related to innate immune mechanisms inherent in
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tskin, specifically in skin stromal cells and not hematopoietic cells, and is likely related to the
capacity of CRAMP to restrict VV dissemination.
TNFα exerts its effects through binding to a pair of specific receptors, TNFR1 and TNFR2
(Faustman and Davis, 2010). We elected to perform our initial experiments in TNFR1−/−
mice because VV is commonly used to vaccinate humans via skin scarification and
keratinocytes express almost exclusively TNFR1. It has been reported that keratinocytes can
serve as a first line of defense following VV skin infection in that they are less-permissive to
VV infection and replication in vitro as compared to dermal fibroblasts and microvascular
endothelial cells (Liu et al., 2005). The epidermis of normal skin contains low levels of
TNFα, while cutaneous infection can greatly increase its synthesis and release from
keratinocytes (Kock et al., 1990; Nestle et al., 2009). One explanation of our results is that
disruption of the TNFα/TNFR1 pathway makes skin stromal cells more susceptible to VV
infection and leads to virus dissemination to dermal and subcutaneous tissues. Reduced
expression of the CRAMP gene in the skin of TNFR1−/− mice following VV scarification
supports this hypothesis.
Specifically, VV-specific Ab production and T cell recruitment and function did not prove
to cause the impaired cutaneous immune response to VV seen in TNFR1−/− mice. We did
observe, however, that TNFR1−/− mice did not produce IgG1 subclass antibodies to VV,
resulting in an overall lower total VV-specific Ab titer. Similar defects in primary antibody
responses have been reported for TNFR1−/− mice exposed to Herpes Simplex virus
(Lundberg et al., 2007) and schistosome vaccine (Street et al., 1999). These authors
proposed that TNFR1−/− mice have defects in the follicular dendritic cell network and
germinal center formation in lymph nodes, which could affect Ab responses. However, the
overall humoral response was not significantly different between TNFR1−/− and WT mice
in the two week following scarification when the lesions differences became manifest, and
was sufficient to protect mice from subsequent lethal intranasal VV challenge. The results of
T cell studies were more intriguing because TNFR1−/− mice showed an enhanced T cell
response to VV scarification as compared to WT mice. TNFα has been described as a
negative regulator of type 1 immune responses in other infectious models. TNFα −/− mice
exhibited an uncontrolled type I immune syndrome to pulmonary mycobacterium infection
(Zganiacz et al., 2004) and TNFR1/R2 double knockout mice displayed expanded viral
specific T cells in the spleen following choriomeningitis virus (LCMV) infection (Singh and
Suresh, 2007). The mechanism by which TNFα regulates T cell activity is not fully
understood, and the reason why TNFR1−/− mice have enhanced type I responses following
VV scarification remains to be elucidated.
Our BM reconstitution experiments revealed that the primary cells responding to TNFα/
TNFR1 signaling following VV scarification to limit viral propagation are resident skin
cells, not hematopoietic cells. In preliminary studies we have also demonstrated that TNFα
−/− mice develop large skin lesions after VV scarification similar to those seen in TNFR1−/
− mice (Figure S3a). We set up BM reconstitution experiments with TNFα −/− mice to
further study this phenotype. Consistent with the results of WT BM → TNFR1−/− mice,
WT BM → TNFRα−/− mice developed significantly larger skin lesions with higher virus
load at adjacent skin than the control WT BM → WT mice following VV scarification.
However, unlike TNFR1 BM → WT mice, TNFα−/−BM → WT mice also developed larger
skin lesions with higher virus counts compared to control chimeric mice (Figure S3b and
S3c). Therefore, while the target of TNFα action is restricted to skin stromal components,
the source of TNFα produced in response to VV infection would appear to include both
hematopoietic cells and radioresistant skin elements. More work is needed to understand the
difference between TNFR1−/− mice and TNFα−/− mice upon VV scarification.
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long-lived bone marrow-derived epidermal dendritic cells. As LC are relatively
radioresistant, we may expect that a fraction of the epidermal LC present in the chimeric
mice should be of host origin (Poulin et al., 2007). However, the fact that LC express
predominantly TNFR2, and thus would not show altered function in TNFR1 −/− mice,
would indicate that altered LC function is not the source of impaired cutaneous response in
TNFR1−/− mice or WT BM→ TNFR1−/− chimeric mice (Wang et al., 1996).
To our knowledge, this is previously unreported that TNFR1 is essential for efficient and
effective host defense to cutaneous VV infection. Our results indicate that restriction of VV
propagation by resident skin cells is the specific point in the immune cascade that is
defective in TNFR1−/− mice. We feel the data presented indicate TNF signaling plays an
important role in regulating local innate immune responses in skin and should be the target
of investigation in other models of skin infection. Understanding the immune mechanisms of
VV resistance in skin and the role of TNFα will support the development of safer and more
effective vaccination strategies. Furthermore, these findings may have important
implications regarding the use of TNFα antagonists in the treatment of chronic inflammatory
disorders, which may present a currently unappreciated risk for the development of EV-like
responses.
Materials and Methods
Mice
All mice used have a C57BL/6 genetic background. TNFR1 deficent (TNFR1−/−) mice,
TNFα deficient (TNFα −/−) mice, Thy1.2+ CD45.2+ B6 mice and Thy1.2+ CD45.1+
congenic B6 mice were originally obtained from Jackson Laboratory (Bar Harbor, Maine)
and bred in a biosafety level 1 (BL-1) facility at Harvard Medical School (HMS). All mice
were handled in accordance with guidelines set out by the Center for Animal Resources and
Comparative Medicine at HMS.
Viruses and Viral infection
Recombinant VV expressing EGFP (GFP-VV) and WR-VV stocks were expanded and
titered by standard procedures (Liu et al., 2005). Modified Vaccinia Ankara (MVA:
ACAM3000MVA) was expanded and titered using DF-1 cells (ATCC, Manassas, VA). The
mice were immunized with 5×106 pfu of VV or MVA by scarification at the base of the tail
as described (Tian et al., 2009). In some experiments, C57BL/6 WT mice were injected i.p.
with 250µg anti-mouse TNFα Ab (clone XT 3.11,) or isotype control antibody (clone
HRPN) (Bio X cell, West Lebanon, NH) 1h before and every 3 d after WR-VV scarification.
This dose was selected as the standard for in vivo blockade of TNFα in other mouse models
(Lundberg et al., 2007). Following VV scarification, lesions were measured with a
millimeter ruler every 2–4 days. For challenge experiments, mice were anesthetized with
isoflurane and inoculated intranasally with 2×106 pfu of WR-VV as previously described
(Tian et al., 2009).
Quantitative PCR for determination of viral load
Viral load of various organs was determined by real-time PCR, as previously described
(Tian et al., 2009).
Measurement of vaccinia virus-specific antibody
Vaccinia virus-specific antibody levels were determined at the indicated time points by
ELISA, as previously described (Tian et al., 2009).
Tian et al. Page 7
J Invest Dermatol. Author manuscript; available in PMC 2012 November 1.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
tIn vitro restimulation assay
VV-specific cytokines were determined by in vitro restimulation assay, as previously
described (Tian et al., 2009).
Flow cytometry
Single cell suspension from VV inoculated tail skin was prepared as previously described
(Liu et al., 2010). To detect VV-specific CD8+ T cells, single cell suspensions from ILN,
spleen and skin of immunized mice were stained with PE-conjugated B8R-pentamer
(Proimmune, Oxford, U.K) as previously described (Freyschmidt et al., 2010). To detect
Tregs, the cells were stained with antibodies to mouse FoxP3 (APC) (eBioscience, San
Diego, CA) as well as CD4(FITC), CD25 (PE) and CD3 (PerCP) (BD Biosciences, San
Diego, CA) according to the manufacture’s protocol. For intracellular IFNγ and Granzyme
B staining, skin cells were fist stimulated with PMA and ionomycin (eBioscience) in the
presence of GolgiStop (BD Biosciences) for 5h, then stained with antibodies to mouse IFNγ
(APC) or Granzyme B (APC) in addition to CD8 (FITC), B8R-pentamer (PE) and and B220
(PerCP) from BD Biosciences. The stained cells were acquired on a FACSCanto (BD
Biosciences) and analyzed with FlowJo (Version 6.4.7, Tree star, Ashland, OR).
Immunohistochemistry
Inoculated skin was harvested from three to four mice per group at each time point. Skin
was preserved in formalin, embedded in paraffin, sectioned, and stained with H&E, anti-
CD3 antibody (DAKO, Carpinteria, CA) and anti-GFP (Clontech, Palo Alto, CA) as
previously described (Tian et al., 2009).
Bone Marrow Chimeras
Adult congenic B6 (CD45.1) mice were lethally irradiated (900–1000 Rad) and injected
intravenously with 5–10 × 106 bone marrow (BM) cells from age and gender matched donor
TNFR1−/− (CD45.2) or TNFα−/− (CD45.2) mice. In the case of WT BM→TNFR1−/− or
WT BM→ TNFα−/− chimeric mice, TNFR1−/− or TNFα−/− mice were used as recipients
and reconstituted with BM cells from donor congenic B6 (CD45.1) mice. Recipient B6 mice
reconstituted with BM from donor B6 mice that express different hematopoietic markers
(CD45.1 or CD45.2 accordingly) were used as controls. The level of blood chimerism was
determined as previously described ((Poulin et al., 2007). 96–98% chimerism for all mice
can be achieved 8 wks after BM reconstitution.
Real-time RT-PCR to detect CRAMP gene expression
Total RNA was extracted from skin with RNeasy Lipid Tissue Mini Kit (Qiagen, Valencia,
CA). CRAMP gene expression was measured as previously described (Howell et al., 2006).
CT values for the CRAMP gene were normalized to the reference gene cyclophilin A as
described previously (Liu et al., 2006). CRAMP gene expression in the distant skin of WT
mice was used as a baseline.
Statistics
The significance of observed differences between indicated groups was assessed by an
unpaired Student’s t test. Tests were 2-tailed with a confidence interval of 95%. P values <
0.05 were considered significant. Statistical analyses were performed with Prism software
(v4.0, Graphpad Software, Inc., La Jolla, CA)
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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tNonstandard abbreviations used
AD atopic dermatitis
EV eczema vaccinatum
ILN inguinal lymph node
LC Langerhan cell
MVA Modified Vaccinia Ankara
TNFR TNF receptor
VV vaccinia virus
WR Western Reserve strain
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tFigure 1. TNFR1−/− mice developed markedly larger skin lesions with higher virus counts
following VV scarification
5×106 pfu of WR-VV was applied to the base of the tail by scarification for all studies. At
indicated time points,(a) Photographs were taken and (b) skin lesions were measured. (c)
Numbers of satellite lesions were recorded on day 14. (d) WT mice were treated with anti-
TNFα or control Ab before and following VV scarification and lesion size was measured.
VV DNA copy number was determined by quantitative PCR in (e) inoculated and (f)
adjacent skin following VV scarification. Error bars represent mean ± SEM. n=5 per group.
* P < 0.05, ** P < 0.01, *** P < 0.001, ns= not significant.
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tFigure 2. The altered vaccinia virus-specific antibody response observed in TNFR1−/− mice
following scarification did not affect survival of immunized mice challenged with intranasal VV
(a) 5×106 pfu of WR-VV was applied to TNFR1−/− and WT mice by scarification. The
level of VV-specific antibody in the sera of individual mice was measured by ELISA. (b)
Six weeks after scarification, TNFR1−/− and WT mice were challenged with 2×106 pfu of
WR-VV by intranasal inoculation. Naive TNFR1−/− and WT were used as controls. The
body weight and survival of the mice were recorded daily and plotted. Error bars represent
mean ± SEM. n=5 per group. Representative results of three independent experiments are
shown. * P < 0.05, ** P < 0.01, *** P < 0.001.
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tFigure 3. Type 1 T cell immune response was enhanced in TNFR1−/− mice following VV
scarification
5×106 pfu of WR-VV was applied to TNFR1−/− and WT mice by scarification. At
indicated time points, spleens and ILNs were harvested for (a) in vitro restimulation to
detect VV-specific IFNγ and (b) B8R-pentamer staining to identify VV-specific CD8+ T
cells. (c) The absolute number of CD8+B8R+ cells was plotted . (d) 5×106 pfu of MVA was
applied to TNFR1−/− and WT mice by scarification. At indicated time points, in vitro
restimulation assay was performed to detect VV-specific IFNγ from spleens and ILNs. Error
bars represent mean ± SEM. n=3-5 per group. * P < 0.05, ** P < 0.01, *** P < 0.001, ns =
not significant.
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tFigure 4. T cell homing to the VV inoculation site did not depend on TNFR1
5×106 pfu of WR-VV was applied to TNFR1−/− and WT mice by scarification. (a) At day
6, CD3+ cells (brown) were identified in the inoculated skin using immunohistochemistry.
Representative photographs of three mice per group are shown. Bar = 20µm (b) CD4+ and
CD8+ T cells and (c) VV-specific CD8+ T cells (CD8+ B8R-pentamer+) recruited to the
inoculation site were measured using flow cytometry at different time points. Plots shown
are gated on leukocytes using side and forward scatter. Representative results of two
independent experiments are shown. n= 3–5 per group.
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tFigure 5. Impaired cutaneous response to VV scarification of TNFR1−/− mice is related to
resident skin cells
WR-VV was applied to BM reconstituted chimeric mice by scarification. (a) Lesion size and
(b) Virus load at day 12 were determined. (c) GFP-VV was applied to WT and TNFR1−/−
mice by scarification, H&E and anti-GFP Ab staining were used to identify VV infected
cells (brown) at day 5. Bars: WT top = 100 µm, middle and bottom = 25µm; TNFR1−/− top
= 100 µm, middle and bottom pairs = 10µm. (d) skin samples from WR-VV inoculated mice
were harvested for measurement of CRAMP gene expression. Error bars represent mean ±
SEM. n=4–5 per group. * P < 0.05, ** P < 0.01, *** P < 0.001, ns= not significant.
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